Get the Stockscreener App
4.085
12.42%
0.4513
After Hours:
3.95
-0.135
-3.30%
Molecular Partners Ag Adr stock is traded at $4.085, with a volume of 80,700.
It is up +12.42% in the last 24 hours and up +10.11% over the past month.
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.
See More
Previous Close:
$3.6337
Open:
$3.98
24h Volume:
80,700
Relative Volume:
19.55
Market Cap:
$164.93M
Revenue:
$7.80M
Net Income/Loss:
$-69.02M
P/E Ratio:
-1.9077
EPS:
-2.1413
Net Cash Flow:
$-66.61M
1W Performance:
+13.80%
1M Performance:
+10.11%
6M Performance:
+0.12%
1Y Performance:
-33.25%
1-Day Range:
$3.80
$4.72
1-Week Range:
$3.6337
$4.72
52-Week Range:
$3.36
$6.24
Molecular Partners Ag Adr Stock (MOLN) Company Profile
Name
Molecular Partners Ag Adr
Sector
Industry
Phone
-
Address
-
Compare MOLN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MOLN
Molecular Partners Ag Adr
|
4.085 | 135.90M | 7.80M | -69.02M | -66.61M | -2.1413 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Molecular Partners Ag Adr Stock (MOLN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-30-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Aug-29-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| May-25-22 | Upgrade | Credit Suisse | Underperform → Neutral |
| Apr-27-22 | Downgrade | Credit Suisse | Neutral → Underperform |
| Jul-13-21 | Initiated | Cowen | Outperform |
| Jul-12-21 | Resumed | SVB Leerink | Outperform |
View All
Molecular Partners Ag Adr Stock (MOLN) Latest News
Molecular Partners Reports Q3 2025 Financial Results and Clinical Progress, with DLL3-Targeting Radio-DARPin MP0712 Phase 1 Launch Expected in 2025 - GlobeNewswire Inc.
Molecular Partners (NASDAQ:MOLN) Stock Price Down 2.1% – Here’s What Happened - Defense World
Molecular Partners AG (MOLNZ.XC) Stock Price, News, Quote & History - Yahoo
Molecular Partners (NASDAQ:MOLN) Trading 1.5% HigherHere's What Happened - MarketBeat
Molecular Partners (NASDAQ:MOLN) Price Target Cut to $4.00 by Analysts at JPMorgan Chase & Co. - MarketBeat
Leerink Partnrs Has Bullish Estimate for MOLN Q3 Earnings - MarketBeat
Leerink Partnrs Issues Positive Outlook for MOLN Earnings - Defense World
EHang, Molecular Partners And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Benzinga
Why Serina Therapeutics Shares Are Trading Higher By Over 25%; Here Are 20 Stocks Moving Premarket - Benzinga
Molecular Partners Ag shares rise 3.64% intraday after Voyager Therapeutics expands Alzheimer's disease franchise. - AInvest
Molecular Partners (NASDAQ:MOLN) Stock Price Down 3.4% – Should You Sell? - Defense World
Molecular Partners and Orano Med Present Promising Preclinical Data on MP0726, a Radio-DARPin Candidate for Ovarian Cancer Treatment - AInvest
Molecular Partners shares rise 1.93% after-hours after presenting positive data from ongoing Phase 1/2A trial. - AInvest
Molecular Partners Cuts 40 Jobs, Extends Cash Reach to 2028 - AInvest
Molecular Partners Ag shares rise 6.71% intraday after MIT and Recursion release Boltz-2 AI model. - AInvest
US NYSE/NASD Stock Directory - Minichart
Walmart, Deere, Applied Materials set to report earnings Thursday By Investing.com - Investing.com Nigeria
Walmart, Deere, Applied Materials set to report earnings Thursday - Investing.com
Molecular Partners' AACR 2025 Breakthroughs: Radio-DARPins and Smart T Cell Engagers Ignite Oncology Potential - AInvest
Here's Why Molecular Partners AG Sponsored ADR (MOLN) Could be Great Choice for a Bottom Fisher - Yahoo Finance
J.P. Morgan Keeps Their Buy Rating on Novo Nordisk (0QIU) - The Globe and Mail
TD Cowen maintains Buy on Molecular Partners, target CHF15 - Investing.com
Molecular Partners (MOLN) Stock Forecast and Price Target 2025 - MarketBeat
symbol__ Stock Quote Price and Forecast - CNN
Molecular Partners: Sellers Have Disappeared, Enterprise Value Below Zero (NASDAQ:MOLN) - Seeking Alpha
US stock market gainers for the last week of April 2022 - Nairametrics
Novartis and Molecular Partners report positive topline data from Phase 2 study for ensovibep (MP0420), a DARPin antiviral therapeutic for COVID-19 - Novartis
Citi Appointed as Depositary Bank for Molecular Partners AG’s ADR Programme - Business Wire
Molecular Partners AG Sponsored ADR (MOLN) - Zacks Investment Research
Molecular Partners (MOLN) Earnings Date and Reports 2025 - MarketBeat
Molecular Partners (MOLN) Competitors and Alternatives 2025 - MarketBeat
MOLN Stock Price and Chart — NASDAQ:MOLN - TradingView
Novartis and Molecular Partners announce start of EMPATHY clinical trial for ensovibep for the treatment of COVID-19 - Novartis
Valneva SE (VALN) Stock Price, News, Quote & History - Yahoo
Novartis announces collaboration with Molecular Partners to develop two DARPin® therapies designed for potential use against COVID-19 - Novartis
PDS Biotechnology (PDSB) Short Interest Ratio and Volume 2025 - MarketBeat
Conference Calls and Individual Investors - MarketBeat
RocheDoing now what patients need next - Roche
Molecular Partners Ag Adr Stock (MOLN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.64%
0.35%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):